 | |
| Clinical data | |
|---|---|
| Trade names | Cervagem |
| Other names | methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Pessary |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.058.869 |
| Chemical and physical data | |
| Formula | C23H38O5 |
| Molar mass | 394.552 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is ananalogue ofprostaglandin E1.
It is used as a treatment forobstetric bleeding.[citation needed]
It is used withmifepristone to terminate pregnancy up to 24 weeks gestation.[2]
Vaginal bleeding, cramps, nausea, vomiting,[3] loose stools or diarrhea,[3] headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mildpyrexia.[3] Rare: Uterine rupture, severehypotension, coronary spasms with subsequentmyocardial infarctions.[citation needed]
